TY  - JOUR
AU  - De Santis, Alessandro
AU  - Zhu, Lei
AU  - Tao, Jianxin
AU  - Reißfelder, Christoph
AU  - Schölch, Sebastian
TI  - Molecular subtypes of intrahepatic cholangiocarcinoma.
JO  - Trends in molecular medicine
VL  - 31
IS  - 8
SN  - 1471-4914
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - DKFZ-2025-00379
SP  - 755-769
PY  - 2025
N1  - #EA:A430#LA:A430# / 2025 Aug;31(8):755-769
AB  - Intrahepatic cholangiocarcinoma (iCCA) presents in two clinically distinct subtypes: large duct (LD-iCCA) and small duct (SD-iCCA). These subtypes exhibit significant molecular, genetic, and histopathological differences that impact patient prognosis and treatment responsiveness. This review advocates for a subtype-specific approach to iCCA research and clinical management, including tailored therapeutic strategies that consider distinct genetic profiles and tumor microenvironments. Current therapeutic approaches hold promise, yet efficacy varies by subtype. Additionally, subtype-specific molecular diagnostics, including DNA methylation-based classifiers and transcriptomic sequencing, have shown potential in refining iCCA subclassification, thereby guiding precision medicine efforts. This article outlines existing clinical trials, key research trajectories, and future directions for developing more effective subtype-adapted therapies for iCCA.
KW  - clinical trial (Other)
KW  - intrahepatic cholangiocarcinoma (Other)
KW  - molecular targeted therapy (Other)
KW  - mutation (Other)
KW  - survival (Other)
KW  - translational research (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:39955217
DO  - DOI:10.1016/j.molmed.2025.01.008
UR  - https://inrepo02.dkfz.de/record/298945
ER  -